Moreover, GEN treatment increases the expression of several KATs, augmenting the acetylation of histones H3 and H4 at the promoters of specific tumor suppressor genes and consequently their reexpression, including p16, p21, and BTG3 (B-Cell translocation gene 3), a negative regulator of E2F-1 signaling, in prostate cancer cell lines (69, 77). Here, BTG3 is linked to Familial prostate cancer.